These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35866713)

  • 1. Rheumatoid Arthritis Disease Activity and Hospitalized Infection in a Large US Registry.
    Yun H; Chen L; Roy JA; Greenberg J; Harrold LR; George MD; Curtis JR
    Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1639-1647. PubMed ID: 35866713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.
    Curtis JR; Chen L; Greenberg JD; Harrold L; Kilgore ML; Kremer JM; Solomon DH; Yun H
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):310-319. PubMed ID: 28028867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.
    Kavanaugh A; Keystone E; Greenberg JD; Reed GW; Griffith JM; Friedman AW; Saunders KC; Ganguli A
    Rheumatology (Oxford); 2017 Jul; 56(7):1095-1101. PubMed ID: 28340006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.
    Ranganath VK; Maranian P; Elashoff DA; Woodworth T; Khanna D; Hahn T; Sarkisian C; Kremer JM; Furst DE; Paulus HE
    Rheumatology (Oxford); 2013 Oct; 52(10):1809-17. PubMed ID: 23813577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.
    Accortt NA; Lesperance T; Liu M; Rebello S; Trivedi M; Li Y; Curtis JR
    Arthritis Care Res (Hoboken); 2018 May; 70(5):679-684. PubMed ID: 28960869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target.
    Xiang Y; Wang Q; Li H; Duan X; Fang Y; Yang P; Li Q; Wu R; Huo Y; Shi X; Wu Z; Wang Y; Jiang N; Hsieh E; Li M; Tian X; Zeng X;
    Int J Rheum Dis; 2020 Dec; 23(12):1719-1727. PubMed ID: 33034424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
    Yun H; Chen L; Xie F; Patel H; Boytsov N; Zhang X; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):166-175. PubMed ID: 31566905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.
    Kay J; Morgacheva O; Messing SP; Kremer JM; Greenberg JD; Reed GW; Gravallese EM; Furst DE
    Arthritis Res Ther; 2014 Feb; 16(1):R40. PubMed ID: 24485007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry.
    Curtis JR; Fiore S; Ford K; Janak JC; Chang H; Pappas DA; Blachley T; Emeanuru K; Bykerk VP
    J Clin Rheumatol; 2023 Jun; 29(4):e47-e51. PubMed ID: 37000177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI).
    Pope JE; Rampakakis E; Movahedi M; Cesta A; Sampalis JS; Bombardier C;
    Rheumatology (Oxford); 2021 Feb; 60(2):717-727. PubMed ID: 32789456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
    Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
    Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry.
    Harrold LR; Shan Y; Rebello S; Kramer N; Connolly SE; Alemao E; Kelly S; Kremer JM; Rosenstein ED
    Rheumatol Int; 2020 Aug; 40(8):1239-1248. PubMed ID: 32449040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.
    Harrold LR; Reed GW; Shewade A; Magner R; Saunders KC; John A; Kremer JM; Greenberg JD
    J Rheumatol; 2015 Jul; 42(7):1090-8. PubMed ID: 25934829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
    Solomon DH; Reed GW; Kremer JM; Curtis JR; Farkouh ME; Harrold LR; Hochberg MC; Tsao P; Greenberg JD
    Arthritis Rheumatol; 2015 Jun; 67(6):1449-55. PubMed ID: 25776112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.